Quarter

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

– Advanced first-in-class Boltbody ISAC into the clinic in 2020 and continued to expand pipeline of pioneering immuno-oncology assets –

– Reported positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody ISAC BDC-1001 in ongoing Phase 1/2 clinical trial in early 2021; monotherapy dose expansion and anti-PD-1 antibody combination parts of study expected to start in 2H, 2021 –

REDWOOD CITY, Calif., March 31, 2021 (GLOBE NEWSWIRE) —

BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NESS ZIONA, Israel–(BUSINESS WIRE)–Mar 31, 2021–

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.

“2020 was a tremendous year of growth for BiomX, as we expanded our pipeline with programs in cystic fibrosis and atopic dermatitis, both designed to address unmet medical needs,” said Jonathan Solomon, Chief Executive Officer of BiomX. “Fueled by the rapid development capabilities of our novel BOLT platform, we

XpresSpa Group Provides Business Update and Announces Fourth Quarter 2020 Financial Results

Eleven XpresCheck Wellness Centers Currently Operating with Two Additional Locations to Open Soon

Positioned to launch New Travel Health and Wellness Brand; Mobile App and First Two Locations Expected to Launch Late Summer / Early Fall 2021

Strong Liquidity Position with Cash Balance of Approximately $90 Million as of December 31, 2020

Recognize Deferred Revenue from XpresCheck during the First Half of 2021

Webcast and Conference Call Scheduled for 4:30 PM ET Today

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA), a health and wellness company, today provided a business update and announced that it

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

Recent Highlights

  • AgeX entered into a sponsored research agreement with The Ohio State University using AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function. Loss of non-shivering thermogenic BAT, also known as brown or good fat, in humans

Frequency Therapeutics Supplies Enterprise Updates and Reports Fourth Quarter and Full Year 2020 Fiscal Results

WOBURN, Mass.–(Enterprise WIRE)–Mar 29, 2021–

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a medical-stage biotechnology organization concentrated on harnessing the body’s innate biology to repair service or reverse injury brought on by a wide variety of degenerative diseases, right now announced company updates and economic effects for the fourth quarter and calendar year ended December 31, 2020.

“We a short while ago attained worthwhile info from two clinical experiments in people with sensorineural listening to decline that have delivered us with important learnings that now are informing our upcoming growth strategies for Fx-322, specifically around demo design and style and using a

Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates

WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020

Clinical Utility of WAKIX was Expanded with Additional Approval for Treatment of Cataplexy in Adults with Narcolepsy

Enrollment Continues in Phase 2 Trial of Patients with Prader-Willi Syndrome

On Track to Initiate Two Additional Clinical Trials with Pitolisant in 2021

Conference Call and Webcast to be Held Today at 8:30 a.m. ET

PLYMOUTH MEETING, Pa., March 25, 2021 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with

Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau®

Pro Forma Cash Position of $57 Million at December 31, 20201

NEWPORT BEACH, Calif., March 24, 2021 (GLOBE NEWSWIRE) — Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2020.

“Over the past several months, we successfully transformed our business by settling the International Trade Commission case and related litigation, eliminating $127 million of debt and payment

Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates

Expects to present data at multiple scientific conferences in 2021

2020 year-end cash position of $412 million

Further strengthened cash position with $627 million in net IPO proceeds

SEATTLE, March 24, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2020.

“Engineering cells, whether done in vivo or ex vivo, has the potential to transform outcomes for patients across many diseases. We are excited about our significant progress in 2020 in turning

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

– Advanced ALG-010133 and ALG-000184 into the clinic – both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021
– Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initial Public Offering (IPO), inclusive of the underwriters’ exercise of their overallotment option
– Cash, Cash Equivalents and investments of $243.5 million as of December 31, 2020

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly

Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected
by mid-year 2021

Interim data releases expected from PBCAR269A and PBCAR20A in 2021

Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell,
anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma; Phase 1 study expected to be initiated by mid-year 2021

DURHAM, N.C., March 18, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today

Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update

  • Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million.

  • U.S. FDA clearance for IND application for a Phase 1 clinical trial to evaluate LB1901 in relapsed or refractory T-cell lymphoma (RR TCL).

  • Rolling submission of BLA to the FDA initiated for cilta-cel for the treatment of relapsed or refractory multiple myeloma (RRMM).

  • Cash and cash equivalents and time deposits of $505.7 million as of December 31, 2020.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery

PLAYSTUDIOS, Inc. Announces Preliminary Fourth Quarter and Full Year 2020 Results Along With Recent Business Highlights

Fourth Quarter Revenue of $64.0 million and Full Year 2020 Revenue of $269.9 million, representing year-over-year growth of 12.9{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} and 12.7{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} respectively

Company entered the Casual Bingo market in 1Q2021 with its myVEGAS Bingo product, bringing real-world rewards and loyalty benefits to this robust category

PLAYSTUDIOS, Inc. (“PLAYSTUDIOS” or the “Company”), an award-winning developer of free-to-play casual games for mobile and social platforms that offer real-world rewards to loyal players, today announced preliminary financial results for the fourth quarter and full year ended December 31, 2020. The preliminary results are subject to completion of the Company’s year-end financial

22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and …

Key Business and Financial Highlights

  • 22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across the tobacco and hemp/cannabis industry.
  • Securing Modified Risk Tobacco Product (MRTP) authorization for VLN® remains 22nd Century’s number one priority. The Company is highly confident that the FDA is in the final stages of the review process related to its application.
  • 22nd Century is fully prepared and eager to launch VLN® King and VLN® Menthol King within 90 days of receiving MRTP designation. MRTP designation is a catalyst for the VLN® brand and tobacco franchise via partnerships and licensing

Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises

Initiation of Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients Anticipated in the First Quarter of 2021

HST 003 Trial Initiation for Cartilage Regeneration in the Knee Anticipated in the Second Quarter of 2021

Appointment of Industry Leader Dr. Susan Windham-Bannister to Board of Directors

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results

Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  • Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic CAR gamma-delta T cell therapy, interim clinical data expected in 2021

  • Successfully raised $143.6 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gamma-delta T cell therapies

MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) — Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results and provided a business update for the fourth quarter and

Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update

We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year

We have expanded our global Phase 2 clinical trial beyond the U.S., Europe and Israel; opening additional clinical sites in Australia and Canada

Cystic Fibrosis Foundation (CF Foundation) has increased its partial funding of our clinical trial program beyond the U.S. portion to include Europe and Israel

The independent Safety Review Committees for our Phase 2 cystic fibrosis clinical trial program have allowed dose escalation up to the fourth and highest dose level

Cash and cash equivalents of

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update


Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year 2020. Lineage management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2020 financial and operating results and to provide a business update.


“Our goal is to build Lineage into the preeminent allogeneic cell transplant company, and we hit our stride in 2020, reaching significant clinical, manufacturing, and business

22nd Century Team Reports Small business Highlights and Economic Success for the Fourth Quarter and … | Income

Hemp/Hashish Franchise Highlights and Recent Essential Gatherings

Given that reporting 3rd quarter earnings, 22nd Century proceeds to place a renewed emphasis on its hemp/cannabis system to target the upstream segments of the cannabinoid price chain, in specific, in the regions of plant biotechnology investigate, gene modification and engineering, modern plant breeding and improvement, and extraction. The Firm believes that it can differentiate by itself in the hemp/cannabis sector by constructing upon its main energy and abilities in plant science and in the component price chain and via its operational partnerships together with the addition of its new operational lover, CannaMetrix.

22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020

Key Business and Financial Highlights

  • 22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across the tobacco and hemp/cannabis industry.
  • Securing Modified Risk Tobacco Product (MRTP) authorization for VLN® remains 22nd Century’s number one priority. The Company is highly confident that the FDA is in the final stages of the review process related to its application.
  • 22nd Century is fully prepared and eager to launch VLN® King and VLN® Menthol King within 90 days of receiving MRTP designation. MRTP designation is a catalyst for the VLN® brand and tobacco franchise

Health: Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Nasdaq:AQST

News Highlights

  • Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021
  • Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021
  • Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America
  • Sympazan® (clobazam) continues to meet key performance metrics
  • Management to host conference call and webcast at 8:00 a.m. ET on March 10, 2021

WARREN, N.J., March 09, 2021 (News) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing